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Abstract 
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous 
compared to unlabeled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, 
Zevalin
®
 and Bexxar
®
 have been approved for imaging and therapy. A preparation containing 
rituximab, chimeric mAb immunoconjugate suitable for Lu-177 labeling, could provide better imaging 
and therapeutic profile at the same time.  This study was conducted to evaluate prepared lyophilized 
formulations of three rituximab immunoconjugates, intended for immediate Lu-177 labeling, for 
imaging and therapy. 
The results showed preserved antibody structure and suitability for successful radiolabeling with over 
95% radiochemical purity, encouraging further evaluation experiments.  
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Кит-формулации на имуноконјугати на ритуксимаб за радиоимунотерапија на не-Хочкин 
лимфом 
 
Апстракт 
Радиоимунотерапијата (РИТ) на не-Хочкин лимфомите (НХЛ) се смета за понапредна во 
споредба со необележаните терапевтски антитела. До денес, радиообележаните глувчешки 
анти-CD20 моноклонални антитела, Zevalin® and Bexxar® се одобрени за дијагностички и 
терапевтски цели. Препарат кој содржи ритуксимаб, односно конјугат на ова химерно 
моноклонално антитело, погодно за обележување со Lu-177, би можело да обезбеди подобар 
профил на истовремена дијагностика и терапија. Ова истражување беше спроведено за да се 
оценат подготвени кит- формулации на три имуноконјугати на ритуксимаб, наменети за 
непосредно обележување со Lu-177 за дијагностика и терапија. Добиените резултати покажаа 
зачувана структура на антителото и погодност за радиообележување со висок процент на 
радиохемиска чистота, над 95%, охрабрувачки за понатамошни истражувања.  
Клучни зборови: ритуксимаб, кит-формулација, радиообележување, Lu-177, не-Хочкин 
лимфом. 
 
 
Introduction 
 
Although when in the earliest 2000s, Bexar® and Zevalin® have been approved for RIT of NHL by 
the Food and Drug Agency (FDA), it was done with very encouraging results and a high percentage of 
patients who entered the long-term remission [1], still today, there are no new radioimmunoconjugates 
approved for RIT of solid tumors. The above mentioned fact is due to physical, chemical, biological, 
clinical, regulatory and financial constraints that limited the progress of these drugs [2, 3]. 
Accordingly, a development of new formulations of immunoconjugates labeled with radioisotopes is 
essential for progress in therapy/diagnostic of NHL. Non-Hodgkin’s lymphoma is a form of blood 
cancer with origin in lymphatic system. More than 90% of B-cell lymphoma cells express CD20 
receptor which has proven to be an excellent target for the treatment and investigations for treatment 
of NHL have been based on the development of antibody against these antigens [4, 5]. 
Results of these investigations have led to developing of drugs such as rituximab, other anti-CD20 
monoclonal antibodies (mAbs) labeled with 
111
In (
111
In-ibritumomab) for imaging, 
90
Y (
90
Y-
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ibritumomab, Zevalin) for therapy and 
131
I (
131
I-tositumomab, Bexxar) for imaging and therapy, which 
have been approved for use in patients with NHL [6-10]. Rituximab  radioimmunoconjugates are 
among mostly investigate potential therapeutics for RIT. Various radionuclides, among them 
90
Y, 
111
In, 
64
Cu, 
153
Sm, and 
177
Lu [10-16], attached to antibodies have been described or are under 
development. A number of chelating agents have been investigated for labeling antibodies with 
radioisotopes, with various derivatives of the acyclic agent diethylene triamine pentaacetic acid 
(DTPA) and the macrocyclic agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid  (DOTA) 
being the most widely investigated [17]. 
Therapeutic monoclonal antibodies are very complex molecules. Therefore, their integrity is of 
essential importance for the physico-chemical stability in the preparations and subsequent 
immunological and therapeutical potential. Monoclonal antibodies as protein molecules intended for 
therapy are often formulated in aqueous solution to allow ease of use, but because aqueous 
environment can accelerate many degradation processes [18, 19], the common approach of 
stabilization of these therapeutic preparations is lyophilization. The lyophilization process is a process 
which can assure product’s sterility and stability requirements [20].  
In order to obtain 
177
Lu-rituximab radioimmunoconjugates for use in diagnostic/therapeutic purposes, 
different bifunctional chelating agents-anti-CD20 (rituximab) (BFCA-rituximab) were labeled with 
non-radioactive Lu for preliminar chemical characterization. 
While preparations of different derivatives of DOTA and DTPA radioimmunoconjugates has been 
reported [17], chemical characteristics, stability and biodistribution of the prepared 
radioimmunoconjugates have not been explained in details.  
The main goal was to determine the suitability of preparation and labeling procedures for obtaining 
kit-formulation ready for radioactive labeling. 
 
Materials and methods 
 
Materials 
 
p-SCN-Bn-DOTA [2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid], p-
SCN-Bn-DTPA [2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid] and 2-(4-
isothiocyanatobenzyl)-6-methyl-diethylene-triaminepentaacetic acid (1B4M-DTPA) with 94 % purity 
were obtained from Macrocyclics Inc. (NJ, USA). Rituximab was purified from a commercial 
pharmaceutical sample (Mabthera
®
), purchased from Roche Co, CA, USA, using ultrafiltration 
(Ultracel
® 
- 30K, Millipore, Ireland) for concentration and buffer exchange to sterile 0.1 M PBS, pH 
8.0.  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on the 
mini-gel system (GE Healthcare/Amersham Biosciences).  
 
Conjugation of Rituximab to p-SCN-Bn-DOTA, p-SCN-Bn-DTPA and 1B4M-DTPA 
 
The chelating agents were dissolved in 0.1 M PBS (pH 8.0) to final concentration of 10 mg/mL. 
Amounts required to give a 20-fold molar excess over the amount of rituximab (10 mg/mL) were 
added to antibody in 0.1 M PBS (pH 8.0) solution. The mixture was incubated for 16h, at 4°C. 
Purification of the conjugates was made with ultrafiltration (Ultracel
® 
- 30K, Millipore, Ireland), by 
washing with 0.05 M ammonium acetate, pH 7.0, until the absorbance in the ultrafiltrate at 280 nm 
was nearly zero. 
 
Lyophilization Process 
 
The lyophilization was performed using Labconco Free Zone Stoppering Tray Dryer, (USA) using 
protocol described by Park et al., in 2013 [21], modified to our experience. Briefly, the liquid 
immunoconjugates were filled in 10 mL type I glass tubing vials using a fill volume of 1 mL and 
loaded in the freeze-dryer. The temperature was decreased to -40°C and held for 3 h, increased to -
15°C, to allow complete crystallization, thus completing the freezing step in 10 h. The primary drying 
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was performed at temperature of -10°C and the secondary drying at shelf temperature 25°C. Upon 
finishing the process, the vials were kept at 4°C until analysis.  
 
Labelling the BFCA-rituximab conjugates with non-radioactive Lu  
 
BFCA-rituximab conjugates in a form of freeze-dried preparations were dissolved with 0.9% NaCl, 
and labeled subsequently with 1.0709 µg LuCl3 [equivalent to maximum tolerated dose (MTD) for 
177
Lu (4377.1 MBq)] in a total volume of 1mL at pH 7.0, and incubation for 30 min at room 
temperature (DTPA-rituximab and 1B4M-DTPA-rituximab) and 60 min at 40°C for DOTA-rituximab. 
 
Protein Integrity Test Using SDS-PAGE 
 
SDS-PAGE was performed according to Laemmli protocol [22]. About 5 µL of sample was mixed 
with 10 µL of sample buffer and boiled for 5 min at 95° C. Approximately 5 µL of each preparation 
was applied per lane in 12% bisacrylamide under reducing conditions. Coomassie staining (Coomassie 
Brilliant Blue R-250, Sigma) was used for visualization purposes. As molecular marker Low 
molecular weight marker (Amersham GE Healthcare) was used. 
 
Radiolabeling of the BFCA-rituximab conjugates with Lutetium-177 
 
The radiolabeling of the freeze-dried immunoconjugate was performed after reconstitution in 0.9% 
NaCl, in the presence of acetate ions at pH 7.0 with Lutetium-177 with specific activity of 555 
GBq/mg, at room temperature. The radiolabeled immunoconjugates were obtained with high 
radiochemical yield. The radiochemical purity was determined using size-exclusion (SE-HPLC). 
 
SE-HPLC 
 
The obtained radioimmunoconjugates were characterized with SE-HPLC. Apparatus conditions were: 
column Zorbax Bio Series GF-250; sample volume: 20 μl; mobile phase: 0.9% NaCl flow rate: 1 
mL/min; UV detection at 280 nm and radiometric detection. 
 
Results 
 
After lyophilization, the obtained formulations were dissolved in 0.9% NaCl giving clear to very slight 
opalescent solutions (Figure 1).  
 
 
a)      b) 
Figure 1: а) Immunoconjugates (three types) after lyophilization; b) Immunoconjugates (three types) 
after dissolution. 
 
In order to demonstrate the integrity of the protein and purity after conjugation and lyophilization, 
SDS-PAGE was performed using 12% bisacrylamide gel. The loaded samples were Rituximab (1 
mg/mL, commercial sample), conjugated, p-SCN-Bn-DTPA, p-SCN-Bn-DOTA and 1B4M-DTPA in 
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reconstituted lyophilized formulation and non-radioactive labeled immunoconjugates. On Fig. 2 and 3 
SDS-PAGE patterns for non-labeled and non-radioactive-Lu-labeled conjugates, compared to 
unconjugated rituximab as control sample are shown. 
 
Figure 2: Reducing SDS-PAGE lane patterns for 1) DTPA-rituximab conjugate, after lyophilization, 
2) DOTA-rituximab conjugate, after lyophilization, 3) 1B4M-DTPA-rituximab conjugate, after 
lyophilization, R) rituximab 1 mg/mL, M) molecular marker. 
 
 
 
Figure 3. Reducing SDS-PAGE lane patterns for 1) Lu-DTPA-rituximab conjugate, 2) Lu-DOTA-
rituximab conjugate, 3) Lu-1B4M-DTPA-rituximab conjugate, R) rituximab 1 mg/mL, M) molecular 
marker. 
 
The results showed that all BFCA-rituximab conjugates (before and after labeling) were resolved in 
two distinct Mw species which migrated in two bands (upper band at ~50 kDa and lower band at ~25 
kDa).  As it is shown in Fig. 2, the reducing SDS-PAGE patterns for rituximab, and BFCA-rituximab 
immunoconjugates after lyophilization and reconstitution were with very similar intensity. Similar to 
this, Fig. 3 shows the lane patterns of non-radioactive-Lu-labeled BFCA-rituximab 
immunoconjugates, showing high resemblance patterns before and after labeling. 
The radiolabeling was performed to immunoconjugates with one acyclic, DTPA-rituximab and cyclic, 
DOTA-rituximab BFCAs after reconstitution of the lyophilized preparation with 0.9% saline. 
Representative SE-HPLC profiles of the radiolabeled immunoconjugates are shown in Figure 4-5. In 
the chromatogram obtained, a presence of only one peak is registered, that corresponds to the 
radiolabeled antibody. The radiochemical purity of the immunoconjugate is over 95%, which meets 
quality criteria.  
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Figure 4: SE-HPLC of 
177
Lu-DOTA–rituximab 
 
Figure 5: SE-HPLC of 
177
Lu-DTPA-rituximab 
 
Disscusion 
 
Our study was aimed at assessing physicochemical properties of new lyophilized immunoconjugates 
intended for immediate labeling with Lu-177, with a possibility to be used in NHL treatment. Indeed, 
because of its protein nature, rituximab may go through a variety of chemical and physical degradation 
processes [23]. The preparation of protein therapeutics as lyophilized (freeze-dried) products is often 
essential to obtain stabile pharmaceutical formulation. The lyophilization protocol used did not affect 
structure properties and caused no post-lyophilization modification, as shown in the reducing SDS-
PAGE lane patterns (Fig. 2), in comparison to the result of commercially available rituximab sample. 
No clear indication for antibody degradation after labeling with non-radioactive Lu was also registered 
using reducing SDS-PAGE (Fig. 3). The performed SDS-PAGE electrophoresis in reducing conditions 
confirm the migration behavior typical for IgG antibodies which are comprised of two identical 
subunits, each composed of two polypeptide chains: two heavy and two light chains, linked via 
disulfide bonds [24, 25] The HPLC profiling of all three Lu-177 radioimmunoconjugates, revealed 
only one peak, which corresponds with the radiolabeled conjugate(s), thus manifesting high 
radiochemical purity that is essential for the desired biodistribution of the radiopharmaceuticals. 
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Conclusion 
 
Our results demonstrate that after lyophilization, all three rituximab immunoconjugates remain stable 
and can bind with Lu-177 radioisotope, thus obtaining products with high radiochemical purity. 
Regarding these encouraging results, further experiments will be performed order to demonstrate their 
biological and pharmacological properties. Our results also support the possibility of preparing 
standardized batches of “ready-to-label” rituximab immunoconjugates in order to develop a new 
promising radiopharmaceutical for therapy of NHL. 
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